Benzene Ring Containing Patents (Class 514/576)
-
Patent number: 11660280Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.Type: GrantFiled: September 10, 2018Date of Patent: May 30, 2023Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventor: Rheal A. Towner
-
Patent number: 11219611Abstract: Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.Type: GrantFiled: November 11, 2016Date of Patent: January 11, 2022Assignee: Ocera Therapeutics, Inc.Inventors: Laurene Wang, Stanley Bukofzer, Linda S. Grais
-
Patent number: 11066352Abstract: Embodiments of the present disclosure are related to improved processes for making L-ornithine phenylacetate without using any silver salts or forming any L-ornithine intermediate salts, such as a benzoate salt. The present processes may be used in the commercial scale manufacturing of L-ornithine phenylacetate with high yields and low impurities.Type: GrantFiled: May 7, 2018Date of Patent: July 20, 2021Assignee: Ocera Therapeutics, Inc.Inventors: Ludwig Pilsl, Georg Winkler, Frank Demartin, Vassil Elitzin
-
Patent number: 10751300Abstract: The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, in a first embodiment, the combination of (i) an effective amount of a barbiturate drug, such as phenobarbital or primidone, which solely enhances GABAergic inhibition in a patient suffering a seizure disorder; and (ii) phytocannabinoid cannabidiol (CBD) in a dosage amount sufficient to overcome the hepatic metabolic effect stimulated by the barbiturate drug and provide bioavailable CBD to the patient in clinically efficacious amounts.Type: GrantFiled: January 14, 2016Date of Patent: August 25, 2020Assignee: India Globalization Capital, Inc.Inventors: Ramachandra Mukunda, Ranga Chelva Krishna
-
Patent number: 10555915Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.Type: GrantFiled: August 24, 2010Date of Patent: February 11, 2020Assignees: Hough Ear Institute, Oklahoma Medical Research FoundationInventors: Richard Dana Kopke, Robert A. Floyd
-
Patent number: 10245284Abstract: The present invention relates to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.Type: GrantFiled: August 19, 2015Date of Patent: April 2, 2019Assignee: ALPEX PHARMA S.A.Inventors: Federico Stroppolo, Gabriele Granata
-
Patent number: 9737499Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.Type: GrantFiled: June 19, 2015Date of Patent: August 22, 2017Assignee: Baylor College of MedicineInventor: Brendan Lee
-
Patent number: 9572787Abstract: The invention provides compositions and methods for inhibiting renal fibrosis.Type: GrantFiled: May 21, 2012Date of Patent: February 21, 2017Assignee: Rhode Island HospitalInventor: Shougang Zhuang
-
Patent number: 9504665Abstract: The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment.Type: GrantFiled: September 10, 2013Date of Patent: November 29, 2016Inventor: W. Louis Cleveland
-
Patent number: 9248114Abstract: The present invention refers to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.Type: GrantFiled: August 12, 2013Date of Patent: February 2, 2016Assignee: Action Medicines, S.L.Inventors: Pedro Cuevas Sanchez, Guillermo Gimenez Gallego, Inigo Saenz De Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Patent number: 9034925Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: June 9, 2014Date of Patent: May 19, 2015Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Publication number: 20150126476Abstract: The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.Type: ApplicationFiled: January 2, 2015Publication date: May 7, 2015Inventor: Carmelo Cutrupi
-
Patent number: 9018195Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.Type: GrantFiled: February 14, 2013Date of Patent: April 28, 2015Assignee: AmDerma Pharmaceuticals, LLCInventor: Pedro Cuevas Sànchez
-
Patent number: 8999400Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.Type: GrantFiled: March 2, 2012Date of Patent: April 7, 2015Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Publication number: 20150087680Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: ApplicationFiled: November 26, 2014Publication date: March 26, 2015Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Patent number: 8946262Abstract: Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.Type: GrantFiled: November 29, 2004Date of Patent: February 3, 2015Assignee: Adolor CorporationInventors: David D Christ, Bruce A Wallin, Deanne D Garver, William K Schmidt, David Jackson
-
Patent number: 8927604Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.Type: GrantFiled: January 16, 2013Date of Patent: January 6, 2015Assignee: APR Applied Pharma Research s.a.Inventors: Giorgio Reiner, Alberto Reiner
-
Patent number: 8916611Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.Type: GrantFiled: April 28, 2006Date of Patent: December 23, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, Susan J. Drapeau, Jeffrey C. Marx
-
Patent number: 8912124Abstract: The invention relates to derivatives of (1-cyanocyclopropyl)phenylphosphinic acid of the formula (I) and to salts thereof, of the formula (II), for enhancing stress tolerance in plants to abiotic stress, preferably to drought stress, especially for enhancing plant growth and/or for increasing plant yield.Type: GrantFiled: April 6, 2011Date of Patent: December 16, 2014Assignee: Bayer Cropscience AGInventors: Lothar Willms, Hans-Joachim Zeiβ, Marco Busch, Christopher Hugh Rosinger, Ines Heinemann, Isolde Häuser-Hahn, Martin Jeffrey Hills, Pascal Von Koskull-Döring
-
Patent number: 8912186Abstract: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.Type: GrantFiled: October 16, 2009Date of Patent: December 16, 2014Assignee: Universitaet des SaarlandesInventors: Matthias Engel, Wolfgang Fröhner, Adriane Stroba, Ricardo M. Biondi
-
Patent number: 8889737Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: GrantFiled: December 15, 2011Date of Patent: November 18, 2014Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140336258Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventor: Menachem Shoham
-
Publication number: 20140328823Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140328778Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140329746Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: July 16, 2014Publication date: November 6, 2014Inventors: Xianqi Kong, Xinfu Wu, Abderrahim Bouzide, Isabelle Valade, David Migneault, Francine Gervais, Daniel Delorme, Benoit Bachand, Mohamed Atfani, Sophie Levesque, Bita Samim
-
Patent number: 8841348Abstract: Compositions containing apocynin and paeonol. The compositions may be used for the treatment of inflammatory diseases.Type: GrantFiled: April 7, 2006Date of Patent: September 23, 2014Assignee: AKL Inflammatory LimitedInventor: Nicholas John Larkins
-
Publication number: 20140271762Abstract: A disinfectant wipe is provided including a substrate that is substantially free of polyamides, and an acid anionic disinfectant is adsorbed to the substrate such that the disinfectant readily releases from the substrate to allow at least 65% delivery of the disinfectant when wiped on a surface. The substrate may be a woven, nonwoven, knit fabric, a foam, sponge or film composition and may be formed from polyester, polypropylene, nylon, cotton, rayon, acrylic, or combinations thereof. The acid anionic disinfectant has a pH below 7, below 5, below 3 and below 2. The substrate used to prepare the disinfectant wipe is not pretreated with the disinfectant or a release composition before applying the disinfectant. That is, the disinfectant is not applied and re-applied to ensure release onto a surface. In an embodiment of the invention acid anionic disinfectant is an antimicrobial agent.Type: ApplicationFiled: March 6, 2014Publication date: September 18, 2014Applicant: ECOLAB USA INC.Inventors: David D. McSherry, Junzhong Li, Richard K. Staub, Joy G. Herdt, Sherri L. Tischler
-
Patent number: 8828966Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by modulating the action of the P2X7 and/or P2Y12 receptors of the RPE cells, specifically decreasing the acidity (pHL) of the RPE lysosomes by administering selected receptor antagonists affecting the action of the P2X7 and/or P2Y12 receptors of the RPE. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.Type: GrantFiled: April 27, 2012Date of Patent: September 9, 2014Inventors: Claire Mitchell, Alan Laties
-
Publication number: 20140235636Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Patent number: 8809304Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.Type: GrantFiled: December 15, 2006Date of Patent: August 19, 2014Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masatoshi Kiuchi, Kaoru Marukawa, Nobutaka Kobayashi, Kunio Sugahara
-
Patent number: 8808755Abstract: A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.Type: GrantFiled: February 8, 2011Date of Patent: August 19, 2014Assignee: Virox Technologies Inc.Inventor: Navid Omidbakhsh
-
Patent number: 8802732Abstract: A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural killer (NK) cells is elevated. Specifically, the composition comprises lycopene and resveratrol in the range of 1:10 to 10:1 by molar; more preferably 1:1 to 3:1 by molar, and most preferably at 3:1. Alternatively, the preferred ratio may be expressed as 1:4 to 25:1 by weight; more preferably 2½:1 to 7½:1 by weight, and most preferably at 7½:1. The composition may be formulated for oral intake as a pharmaceutical, dietary supplement or food product and provided in therapeutically effective amounts to a mammal, preferably in a dosage of about 3.5 mg per day per 20 g of a mammalian body mass in a ratio of 2½:1 by weight, which can be translated to about 400 mg to 1000 mg per day for a typical human in need of elevating NK cell activity.Type: GrantFiled: April 13, 2010Date of Patent: August 12, 2014Assignee: Hsiehs Biotech (Singapore) Pte LtdInventor: Kun Lung Hsieh
-
Patent number: 8802105Abstract: The present invention relates to oral antibacterial compositions comprising trihydroxybenzoate derivatives, e.g., useful for the treatment of gum diseases (e.g., gingivitis or periodontitis) and to methods of using such compositions.Type: GrantFiled: March 12, 2013Date of Patent: August 12, 2014Assignee: Forsyth Dental Infirmary for ChildrenInventors: Toshihisa Kawai, Philip P. Stashenko, Yoshitaka Hosokawa, Kazuhisa Ohara
-
Patent number: 8785498Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: July 8, 2013Date of Patent: July 22, 2014Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Publication number: 20140187638Abstract: The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related methods and compositions.Type: ApplicationFiled: June 22, 2012Publication date: July 3, 2014Applicant: GMP-ORPHANInventor: Frederic Marin
-
Publication number: 20140187631Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: ApplicationFiled: February 3, 2012Publication date: July 3, 2014Inventors: Richard D. Kpoke, Robert A. Floyd, Rheal Towner
-
Publication number: 20140179700Abstract: Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, ?-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from an ERK inhibitor, a MEK inhibitor, and a Raf inhibitor. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells are also provided.Type: ApplicationFiled: April 30, 2012Publication date: June 26, 2014Applicant: Duke UniveristyInventor: Rahima Zennadi
-
Publication number: 20140162982Abstract: The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.Type: ApplicationFiled: May 15, 2012Publication date: June 12, 2014Inventor: Carmelo Cutrupi
-
Publication number: 20140163045Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.Type: ApplicationFiled: March 8, 2013Publication date: June 12, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
-
Publication number: 20140135400Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: January 3, 2014Publication date: May 15, 2014Applicant: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Publication number: 20140107027Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: BHI LIMITED PARTNERSHIPInventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
-
Publication number: 20140057959Abstract: The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.Type: ApplicationFiled: September 24, 2013Publication date: February 27, 2014Applicants: UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP, EMS S.A.Inventors: Ednir de Oliveira VIZIOLI, Chung Man Chin, Renato Farina Menegon, Lorena Blau, Jean Leandro Dos Santos, Maria do Carmo Longo
-
Patent number: 8642801Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: GrantFiled: November 5, 2009Date of Patent: February 4, 2014Assignee: BHI Limited PartnershipInventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
-
Patent number: 8637085Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.Type: GrantFiled: March 21, 2012Date of Patent: January 28, 2014Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Patent number: 8633249Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: GrantFiled: September 2, 2009Date of Patent: January 21, 2014Assignee: Oklahoma Medical Research FoundationInventors: Rheal A. Towner, Robert A. Floyd
-
Patent number: 8633250Abstract: Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage.Type: GrantFiled: January 11, 2007Date of Patent: January 21, 2014Assignee: MUSC Foundation for Research DevelopmentInventors: Rick G. Schnellmann, Shougang Zhuang
-
Patent number: 8603947Abstract: A description is given of (4-haloalkyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, Y, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.Type: GrantFiled: July 20, 2011Date of Patent: December 10, 2013Assignee: Bayer Cropscience AGInventors: Hartmut Ahrens, Dieter Feucht, Elmar Gatzweiler, Isolde Haeuser-Hahn, Christopher Hugh Rosinger
-
Patent number: 8580853Abstract: A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia.Type: GrantFiled: June 13, 2011Date of Patent: November 12, 2013Inventor: Howard Phykitt
-
Publication number: 20130296282Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: ApplicationFiled: July 9, 2013Publication date: November 7, 2013Inventor: Pedro Cuevas Sànchez
-
Publication number: 20130295009Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof;Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Torbjorn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT